A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.
ANNÉE
2022
AUTEURS
Hilmi M, Mitry E, Turpin A, Bouché 0, Metges JP, Ghiringhelli F, Trouilloud I, Roth G, Baumgaertner I, Borg C, Ammarguellat H, Guillet M, Rinaldi Y, Lecomte T, Louvet C, Lambert A, Hautefeuille V, Garcia-Larnicol ML, Henriques J , Neuzillet C
CONGRÈS/REVUE
ASCO
LIEN PUBLICATIONS ASSOCIÉES